NYSE 
Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's...
Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) – Stock analysts at William Blair increased their Q1 2026 EPS estimates for Charles River Laboratories International in ...
Charles River Laboratories International (NYSE:CRL – Get Free Report) had its target price upped by equities researchers at Barclays from $145.00 to $155.00 in a research note issued on Thursday ...
Resolution of CRL Manufacturing issues in progress - Type A meeting requested No clinical safety or efficacy concerns raised by FDA MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq:
Algert Global LLC purchased a new position in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) in the fourth quarter, according to its most recent 13F filing with the ...
On Wednesday, 14 May 2025, Charles River Laboratories (NYSE:CRL) presented its strategic insights at...
We plan to present four-year data at the PPMG meeting in June, showing long-term stabilization in...
KeyBanc upgraded also upgraded Entergy (ETR) to Overweight from Sector Weight with an $85 price...
Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with...
- Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3 trial of govorestat in CMT-SORD Deficiency at the Peripheral Nerve ...
